Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia Clinical Trial

Official title:

Phase II Trial of Perifosine in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00873457
• Other study ID #: Pro00015060
• Status: Completed
• Phase: Phase 2
• First received: March 30, 2009
• Last updated: May 19, 2013
• Start date: August 2009
• Est. completion date: April 2013

Study information

• Verified date: May 2013
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Perifosine inhibits the AKT pathway (a way cells communicate with each other). This pathway is felt to be important in the development of several types of cancers including chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is thought perifosine may be able to block this pathway and lead to an improvement in the CLL or SLL. The purpose of this trial is to see if perifosine is an effective treatment for relapsed or refractory CLL or SLL. Another purpose of this study is to look at the effect perifosine has on cells.

Description:

Chronic lymphocytic leukemia and small B-cell lymphocytic lymphoma represent different manifestations of the same disease. CLL/SLL (hereafter denoted by CLL) is a clonal disorder of small B lymphocytes expressing a characteristic morphology and immunophenotype. The B cells express CD19, dim CD 20, dim CD 5, CD 23, CD 43, CD 79a, and weakly express surface immunoglobin. CLL can present asymptomatically in 25% of patients when diagnosed on a complete blood count. It also can present with diffuse painless lymphadenopathy and, in a smaller number of patients, B symptoms.

CLL is characterized by accumulation of circulating B cells predominantly in the G0 phase of the cell cycle. These cells are resistant to apoptosis. CLL has been found to have aberrant signaling in several pathways including NF-kB, Akt/PI3K, and JNK/STAT pathways. Akt is important in promoting CLL survival and viability, as seen in in vitro experiments where blocking its activity results in apoptosis. Thus an AKT inhibitor may lead to increased apoptosis and may have a role in the treatment of this disease.

Treatment options for CLL range from a watch and wait approach to high dose chemotherapy with stem cell support. Currently, there is no consensus on the best treatment regimen, since no treatment has been shown to improve survival in randomized prospective clinical trials. New approaches to treatment, especially those with lower toxicity rates, are needed.

Perifosine has been shown to inhibit or otherwise modify signaling through a number of different signal transduction pathways, including Akt, MAPK, and JNK. These pathways are involved in the development of cancers and resistance to chemotherapy. Perifosine is of particular interest, especially due to the difficulty in discovery of drugs that inhibit these pathways with minimal toxicity. The effect of perifosine on CLL cells has been tested in the laboratory and has been shown to be an active agent against primary CLL cells in vitro.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: April 2013
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A diagnosis of CLL or SLL based on iwCLL diagnostic criteria.

• Prior therapy for CLL (no limit on number of prior regimens).

• Patients requiring therapy, based on at least one of the iwCLL criteria.

• 18 years of age or older.

• Performance status ECOG 0, 1, or 2.

• An estimated or measured creatinine clearance =30 ml/min at study enrollment.

• AST, ALT, and total bilirubin = 2.5 times the upper limit of normal, unless due to CLL/SLL.

• Female subject who is either post-menopausal or surgically sterilized or male or female subject willing to use an acceptable method of birth control for the duration of the study therapy and for 2 weeks after study therapy completion.

Exclusion Criteria:

• Female subject is pregnant or lactating.

• Patient has received other investigational drugs for this disease within 14 days of enrollment.

• Patient with known HIV prior to enrollment.

• Serious medical or psychiatric illness likely to interfere with participation in this clinical study.

• Patients with another malignancy within the last three years (from documentation of remission) other than basal or squamous cell skin cancer or CIS of the cervix or early stage prostate cancer not requiring systemic treatment.

• Patients who underwent allogeneic stem cell transplant and have at least 2% donor cells engrafted will be excluded.

• Significant cardiac or vascular events within 6 months: acute MI, unstable angina, severe peripheral vascular disease (ischemic pain at rest class 3 or worse, non-healing ulcers/wounds, congestive heart failure (NHYA class = 2), uncontrolled cardiac arrhythmias.

• Known severe hypersensitivity to perifosine or any component of the formulation.

• Life expectancy less than six months due to co-morbid illness

• Active autoimmune hemolytic anemia or immune thrombocytopenia, requiring current steroid therapy.

• De novo prolymphocytic leukemia (PLL) or PLL arising from CLL (= 55% prolymphocytes).

• Richter's transformation

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Lymphoma
• Small Lymphocytic Lymphoma

Intervention

Drug:
• perifosine
Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (3)

Lead Sponsor	Collaborator
Daphne Friedman	Keryx / AOI Pharmaceuticals, Inc., Keryx Biopharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response	Per International Workshop on Chronic Lymphocytic Leukemia, Complete Response (CR):normal CBC; absence of the following: clonal lymphocytes in blood and marrow, lymphadenopathy, hepatomegaly or splenomegaly, and constitutional symptoms; and bone marrow has <30% lymphocytes, is normocellular, and is without B-lymphoid nodules. Partial Response(PR): one of the following: decrease lymphadenopathy = 50%; decrease of liver and/or spleen size = 50%, any constitutional symptoms, Polymorphonuclear leukocytes = 1,500/µl or a 50% improvement, or decrease of circulating clonal B lymphocytes = 50% AND one of the following: Platelets = 100,000/µl or a 50% improvement, Hemoglobin = 11.0 g/dl or a 50% improvement, Bone marrow has = 30% lymphocytes, or B-lymphoid nodules, or not done. Overall Response (OR)= CR+PR	after 3 months of treatment	No
Primary	Overall Response	Per International Workshop on Chronic Lymphocytic Leukemia, Complete Response (CR):normal CBC; absence of the following: clonal lymphocytes in blood and marrow, lymphadenopathy, hepatomegaly or splenomegaly, and constitutional symptoms; and bone marrow has <30% lymphocytes, is normocellular, and is without B-lymphoid nodules. Partial Response(PR): one of the following: decrease lymphadenopathy = 50%; decrease of liver and/or spleen size = 50%, any constitutional symptoms, Polymorphonuclear leukocytes = 1,500/µl or a 50% improvement, or decrease of circulating clonal B lymphocytes = 50% AND one of the following: Platelets = 100,000/µl or a 50% improvement, Hemoglobin = 11.0 g/dl or a 50% improvement, Bone marrow has = 30% lymphocytes, or B-lymphoid nodules, or not done. Overall Response (OR)= CR+PR	after 6 months of treatment	No
Secondary	Overall Survival	Overall survival is defined as the length of time between discontinuation of perifosine until death or 2 year's followup, whichever comes first.	up to a maximum of 2 years	No
Secondary	Event-free Survival	Event-free survival will be defined as the length of time between the discontinuation of study treatment and disease progression, next therapy, or death,whichever comes first, up to a maximum of 2 years.	up to a maximum of 2 years	No